LivaNova PLC (NASDAQ:LIVN) Short Interest Update

LivaNova PLC (NASDAQ:LIVN - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 1,580,000 shares, a drop of 18.6% from the February 13th total of 1,940,000 shares. Currently, 2.9% of the company's shares are short sold. Based on an average daily volume of 613,400 shares, the short-interest ratio is presently 2.6 days.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after buying an additional 265,291 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Capital Research Global Investors boosted its stake in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after purchasing an additional 258,730 shares during the last quarter. Geode Capital Management LLC boosted its stake in LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after purchasing an additional 8,331 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after purchasing an additional 107,693 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Remove Ads

LivaNova Stock Down 2.3 %

LivaNova stock traded down $0.95 during midday trading on Friday, reaching $39.48. The stock had a trading volume of 1,140,685 shares, compared to its average volume of 594,262. LivaNova has a 12 month low of $36.85 and a 12 month high of $64.48. The company has a market capitalization of $2.15 billion, a P/E ratio of 94.00 and a beta of 1.10. The company has a fifty day moving average price of $45.31 and a two-hundred day moving average price of $48.75. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LIVN. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Barclays lowered their price objective on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research report on Friday, March 7th. Stifel Nicolaus lowered their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 26th. Finally, Mizuho lowered their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has a consensus rating of "Moderate Buy" and an average price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.